.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XC01_FusidicAcid.FusidicAcid .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XC01_FusidicAcid.FusidicAcid| name: | FusidicAcid |
| ATC code: | J01XC01 | route: | oral |
| n-compartments | 1 |
Fusidic acid is a steroidal antibiotic primarily used for the treatment of infections caused by Staphylococcus species, particularly methicillin-resistant Staphylococcus aureus (MRSA). It is available in oral and topical formulations and is used most commonly in skin, soft tissue, and bone infections. Fusidic acid is still approved for clinical use in several countries.
Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of fusidic acid.
Bulitta, JB, et al., & Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy 57(1) 498–507. DOI:10.1128/AAC.01354-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23147726
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241
Marsot, A, et al., & Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British journal of clinical pharmacology 86(11) 2319–2324. DOI:10.1111/bcp.14319 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32330996